After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
SOURCE InterMune, Inc.
If history repeats itself, the recent weakness in biotech stocks will end with lots more buying.
In 2014 drugmakers long on cash but short on growth bought quick access to markets that would have otherwise taken years to build. Can this continue?
CEO Schwan told Reuters that the company's decision to buy U.S. biotech company InterMune (ITMN) was "exceptional" and not a sign of more ambitious plans for major acquisitions.
Small-cap stocks are experiencing selling pressure this week as volatility rises as world event prey on investor uncertainty.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.